There are 412 resources available
2304P - A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19 -17)
Presenter: Eun Joo Kang
Session: Poster session 08
1760P - Systematic review of quality of life (QoL) inclusion among endpoints, reporting and impact of QoL results in phase III non-inferiority trials of systemic treatments in oncology
Presenter: Jessica Paparo
Session: Poster session 23
2032MO - Correlation of safety and efficacy in atezolizumab therapy across indications
Presenter: Jarushka Naidoo
Session: Mini oral session - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
691P - Efficacy of ABBV-400 monotherapy in patients with MET gene amplified advanced solid tumors
Presenter: John Strickler
Session: Poster session 17
654O - Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study
Presenter: Bob Li
Session: Proffered Paper session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
1322MO - Insights into tumour dissemination and progression using longitudinal Imaging and ctDNA in the TRACERx lung cancer study
Presenter: Wing Kin Liu
Session: Mini oral session 2 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
192P - Impact of oncogenic fibroblast growth factor receptor (FGFR) alterations in patients with advanced solid tumors in a real-world setting
Presenter: Hussein Sweiti
Session: Poster session 01
1988MO - Recruitment discontinuation in TREASURE trial (thoracic radiotherapy with atezolizumab in small cell lung cancer extensive disease) due to unexpected safety data
Presenter: Farastuk Bozorgmehr
Session: Mini oral session 1 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
2316P - Integrating comprehensive cancer genome profiling into clinical practice in an Italian referral center: Results of the first year of the fpg500 programme
Presenter: Camilla Nero
Session: Poster session 08
687P - A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours
Presenter: Johann de Bono
Session: Poster session 17